News | December 26, 2025
Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
It has also been granted permission to conduct trials for booster dose
It’s a two-dose vaccine administered 28 days apart
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
The facility has the capacity to produce one crore doses per day
Subscribe To Our Newsletter & Stay Updated
